BR9601125A - Composto processo para produzir o mesmo composições farmacêuticas para antagonizar o receptor de taquicinina para antagonizar um receptor de neurocinina a para prevenir ou tratar distúrbios de micção distúrbios de asma artrite reumatóide osteoartrite dor enxaqueca tosse sindrome do intestino irritável ou êmese processos para antagonizar receptor de taquicinina em mamíferos para prevenir ou tratar distúrbios de micção em mamíferos para prevenir ou tratar distúbios de asma enxaqueca sindrome do intestino irritávvel dor tosse oe êmese em mamíferos e uso do composto - Google Patents
Composto processo para produzir o mesmo composições farmacêuticas para antagonizar o receptor de taquicinina para antagonizar um receptor de neurocinina a para prevenir ou tratar distúrbios de micção distúrbios de asma artrite reumatóide osteoartrite dor enxaqueca tosse sindrome do intestino irritável ou êmese processos para antagonizar receptor de taquicinina em mamíferos para prevenir ou tratar distúrbios de micção em mamíferos para prevenir ou tratar distúbios de asma enxaqueca sindrome do intestino irritávvel dor tosse oe êmese em mamíferos e uso do compostoInfo
- Publication number
- BR9601125A BR9601125A BR9601125A BR9601125A BR9601125A BR 9601125 A BR9601125 A BR 9601125A BR 9601125 A BR9601125 A BR 9601125A BR 9601125 A BR9601125 A BR 9601125A BR 9601125 A BR9601125 A BR 9601125A
- Authority
- BR
- Brazil
- Prior art keywords
- mammals
- antagonize
- prevent
- disorders
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9143695 | 1995-03-24 | ||
JP20755395 | 1995-07-20 | ||
JP26472795 | 1995-09-18 | ||
JP3003396 | 1996-01-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9601125A true BR9601125A (pt) | 1998-01-06 |
Family
ID=27459171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9601125A BR9601125A (pt) | 1995-03-24 | 1996-03-25 | Composto processo para produzir o mesmo composições farmacêuticas para antagonizar o receptor de taquicinina para antagonizar um receptor de neurocinina a para prevenir ou tratar distúrbios de micção distúrbios de asma artrite reumatóide osteoartrite dor enxaqueca tosse sindrome do intestino irritável ou êmese processos para antagonizar receptor de taquicinina em mamíferos para prevenir ou tratar distúrbios de micção em mamíferos para prevenir ou tratar distúbios de asma enxaqueca sindrome do intestino irritávvel dor tosse oe êmese em mamíferos e uso do composto |
Country Status (17)
Country | Link |
---|---|
US (3) | US5786352A (pt) |
EP (1) | EP0733632B1 (pt) |
KR (1) | KR960034203A (pt) |
CN (1) | CN1140172A (pt) |
AR (1) | AR003937A1 (pt) |
AT (1) | ATE242243T1 (pt) |
AU (1) | AU699611B2 (pt) |
BR (1) | BR9601125A (pt) |
CA (1) | CA2172421A1 (pt) |
DE (1) | DE69628484T2 (pt) |
ES (1) | ES2194937T3 (pt) |
HU (1) | HUP9600732A3 (pt) |
IL (1) | IL117631A (pt) |
MX (1) | MX9601072A (pt) |
NO (1) | NO309272B1 (pt) |
NZ (1) | NZ286256A (pt) |
TW (1) | TW394773B (pt) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
ID25818A (id) * | 1998-03-19 | 2000-11-09 | Takeda Chemical Industries Ltd | Senyawa-senyawa heterosiklik, produksinya dan penggunaannya |
AU5305299A (en) * | 1998-08-26 | 2000-03-21 | Tanabe Seiyaku Co., Ltd. | Naphthyridine derivatives and process for the preparation thereof |
WO2000032192A1 (fr) * | 1998-11-27 | 2000-06-08 | Takeda Chemical Industries, Ltd. | Medicaments |
EP1394150B1 (en) | 1999-02-24 | 2011-01-19 | F. Hoffmann-La Roche AG | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
ATE280158T1 (de) * | 1999-02-24 | 2004-11-15 | Hoffmann La Roche | 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten |
US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
CN1414953A (zh) | 1999-11-03 | 2003-04-30 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和5-羟色胺重摄取的用途 |
EP1103545B1 (en) * | 1999-11-29 | 2003-11-05 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
AU7334901A (en) | 2000-07-11 | 2002-01-21 | Du Pont Pharm Co | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
EP1323429A4 (en) * | 2000-09-26 | 2006-03-22 | Takeda Pharmaceutical | PREVENTION AND / OR REMEDY AGENTS IN RELATION TO AFFECTIVE DISORDERS |
US20040058914A1 (en) * | 2000-12-22 | 2004-03-25 | Takayuki Doi | Combination drugs |
WO2002094799A2 (en) | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
WO2003029254A1 (fr) * | 2001-09-28 | 2003-04-10 | Takeda Chemical Industries, Ltd. | Procede de preparation de composes tricycliques |
WO2003050123A1 (fr) * | 2001-12-10 | 2003-06-19 | Kyorin Pharmaceutical Co., Ltd. | Derives bicycliques fusionnes de pyridine en tant qu'antagonistes du recepteur de la tachykinine |
JP4417720B2 (ja) * | 2002-01-18 | 2010-02-17 | 杏林製薬株式会社 | 縮合二環式ピリミジン誘導体 |
AU2003221204B2 (en) * | 2002-03-26 | 2008-09-18 | Kyorin Pharmaceutical Co., Ltd. | Fused bicyclic pyridine derivative as tachykinin receptor antagonist |
CA2514547A1 (en) | 2003-01-28 | 2004-08-12 | Takeda Pharmaceutical Company Limited | Receptor agonists |
TWI280239B (en) | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
US20060148783A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20070142367A1 (en) * | 2003-11-10 | 2007-06-21 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20050113365A1 (en) * | 2003-11-10 | 2005-05-26 | Sir Isaac Newton Enterprises Llc | Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome |
US20060148782A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both |
US20060148781A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder in a non-human mammal |
MX2007000428A (es) | 2004-07-15 | 2008-03-05 | Amr Technology Inc | Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina. |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
CA2615403C (en) | 2005-07-15 | 2015-06-16 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
KR20080043852A (ko) | 2005-09-23 | 2008-05-19 | 에프. 호프만-라 로슈 아게 | 신규 투여 제형 |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP2109608B1 (en) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体 |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
JPWO2010016552A1 (ja) * | 2008-08-07 | 2012-01-26 | 武田薬品工業株式会社 | 過敏性腸症候群治療薬 |
EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
EP2429293B1 (en) | 2009-05-12 | 2014-10-29 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
KR101485645B1 (ko) | 2009-10-14 | 2015-01-22 | 머크 샤프 앤드 돔 코포레이션 | p53 활성을 증가시키는 치환된 피페리딘 및 그의 용도 |
CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制 |
HUE044815T2 (hu) | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
CA2830027C (en) | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
LT2925888T (lt) | 2012-11-28 | 2018-01-10 | Merck Sharp & Dohme Corp. | Vėžio gydymo kompozicijos ir būdai |
BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
UA121309C2 (uk) | 2014-02-03 | 2020-05-12 | Вітае Фармасьютікалс, Ллс | Дигідропіролопіридинові інгібітори ror-гамма |
UA118989C2 (uk) | 2014-10-14 | 2019-04-10 | Вітае Фармасьютікалс, Інк. | Дигідропіролопіридинові інгібітори ror-гамма |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
SG11201705780PA (en) | 2015-02-03 | 2017-08-30 | Pfizer | Novel cyclopropabenzofuranyl pyridopyrazinediones |
EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
MX2018006223A (es) | 2015-11-20 | 2018-12-19 | Vitae Pharmaceuticals Inc | Moduladores de ror-gamma. |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
IL298639A (en) | 2017-07-24 | 2023-01-01 | Vitae Pharmaceuticals Llc | Inhibitors of gamma ror |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
US20210277009A1 (en) | 2018-08-07 | 2021-09-09 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
US20210309688A1 (en) | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES431307A1 (es) * | 1973-11-16 | 1976-09-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevos derivados de quinoleina. |
DE2357253A1 (de) * | 1973-11-16 | 1975-05-22 | Thomae Gmbh Dr K | Neue chinolinderivate |
DE2617101A1 (de) * | 1976-04-17 | 1977-11-17 | Thomae Gmbh Dr K | Neue naphthyridine |
DE2638828A1 (de) * | 1976-08-28 | 1978-03-09 | Thomae Gmbh Dr K | Neue thieno-pyridine |
DE2722416A1 (de) * | 1977-05-18 | 1978-11-30 | Thomae Gmbh Dr K | Neue thiazolo-pyridine |
US4746657A (en) * | 1987-07-13 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic tetrahydroazepinones (and thiones) |
TW241258B (pt) * | 1992-04-15 | 1995-02-21 | Takeda Pharm Industry Co Ltd | |
ATE161530T1 (de) * | 1992-09-04 | 1998-01-15 | Takeda Chemical Industries Ltd | Kondensierte heterozyklische verbindungen, deren herstellung und verwendung |
EP0634402A1 (en) * | 1993-07-14 | 1995-01-18 | Takeda Chemical Industries, Ltd. | Isochinolinone derivatives, their production and use |
TW263498B (pt) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd |
-
1996
- 1996-03-21 DE DE69628484T patent/DE69628484T2/de not_active Expired - Lifetime
- 1996-03-21 ES ES96104500T patent/ES2194937T3/es not_active Expired - Lifetime
- 1996-03-21 AT AT96104500T patent/ATE242243T1/de not_active IP Right Cessation
- 1996-03-21 TW TW085103427A patent/TW394773B/zh active
- 1996-03-21 NO NO961160A patent/NO309272B1/no not_active IP Right Cessation
- 1996-03-21 EP EP96104500A patent/EP0733632B1/en not_active Expired - Lifetime
- 1996-03-22 AU AU48261/96A patent/AU699611B2/en not_active Ceased
- 1996-03-22 MX MX9601072A patent/MX9601072A/es unknown
- 1996-03-22 AR ARP960101863A patent/AR003937A1/es unknown
- 1996-03-22 CA CA002172421A patent/CA2172421A1/en not_active Abandoned
- 1996-03-22 HU HU9600732A patent/HUP9600732A3/hu unknown
- 1996-03-23 CN CN96106081A patent/CN1140172A/zh active Pending
- 1996-03-23 KR KR1019960008047A patent/KR960034203A/ko active IP Right Grant
- 1996-03-24 IL IL11763196A patent/IL117631A/xx not_active IP Right Cessation
- 1996-03-25 BR BR9601125A patent/BR9601125A/pt not_active Application Discontinuation
- 1996-03-25 US US08/621,360 patent/US5786352A/en not_active Expired - Lifetime
- 1996-03-25 NZ NZ286256A patent/NZ286256A/xx unknown
-
1998
- 1998-06-01 US US09/087,894 patent/US6147071A/en not_active Expired - Fee Related
-
2000
- 2000-08-23 US US09/644,306 patent/US6489315B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU4826196A (en) | 1996-10-03 |
DE69628484D1 (de) | 2003-07-10 |
US5786352A (en) | 1998-07-28 |
ES2194937T3 (es) | 2003-12-01 |
AU699611B2 (en) | 1998-12-10 |
NZ286256A (en) | 1999-05-28 |
CN1140172A (zh) | 1997-01-15 |
KR960034203A (ko) | 1996-10-22 |
NO961160D0 (no) | 1996-03-21 |
NO961160L (no) | 1996-09-25 |
HUP9600732A2 (en) | 1997-03-28 |
US6489315B1 (en) | 2002-12-03 |
HU9600732D0 (en) | 1996-05-28 |
ATE242243T1 (de) | 2003-06-15 |
IL117631A (en) | 2000-11-21 |
IL117631A0 (en) | 1996-07-23 |
EP0733632A1 (en) | 1996-09-25 |
EP0733632B1 (en) | 2003-06-04 |
DE69628484T2 (de) | 2004-05-19 |
US6147071A (en) | 2000-11-14 |
MX9601072A (es) | 1997-03-29 |
AR003937A1 (es) | 1998-09-30 |
CA2172421A1 (en) | 1996-09-25 |
HUP9600732A3 (en) | 2000-03-28 |
NO309272B1 (no) | 2001-01-08 |
TW394773B (en) | 2000-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9601125A (pt) | Composto processo para produzir o mesmo composições farmacêuticas para antagonizar o receptor de taquicinina para antagonizar um receptor de neurocinina a para prevenir ou tratar distúrbios de micção distúrbios de asma artrite reumatóide osteoartrite dor enxaqueca tosse sindrome do intestino irritável ou êmese processos para antagonizar receptor de taquicinina em mamíferos para prevenir ou tratar distúrbios de micção em mamíferos para prevenir ou tratar distúbios de asma enxaqueca sindrome do intestino irritávvel dor tosse oe êmese em mamíferos e uso do composto | |
FR2739041B1 (fr) | Procede de nettoyage et d'assainissement de surfaces solides ou d'installations industrielles | |
ES2104424T3 (es) | Compuestos de isoxazolina como agentes antiinflamatorios. | |
MA23942A1 (fr) | Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation | |
ES2139754T3 (es) | 3-fenil-2-isoxazolinas como agentes antiinflamatorios. | |
ID26207A (id) | ESTRATRIENA TERSUBSTITUSI 11β-HALOGEN-7 αTERSUBSTITUTASI, PROSES UNTUK MEMPRODUKSI SEDIAAN FARMASI YANG MENGANDUNG ESTRATRIENA 11β-HALOGEN-7 αINI DAN JUGA PENGGUNAANNYA UNTUK PRODUKSI ZAT-ZAT FARMASI | |
DK0681571T3 (da) | Spiro-substituerede azacykliske forbindelser som tachykininreceptorantagonister | |
NO983003L (no) | Vitronectin-reseptor-antagonister | |
ID26399A (id) | Turunan 1-(1-tersubstitusi-4-piperidinil) metil -4-piperidin, proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan intermedietnya | |
BR9604894A (pt) | Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo | |
BR9611146A (pt) | Métodos composições e/ou artigos de limpeza/sanitização para produto | |
DE69620053D1 (de) | Gefärbte Titanschüppchen, Verfahren zu deren Herstellung, sowie Zusammensetzung, enthaltend Harz und gefärbte Titanschüppchen | |
HUP9802315A3 (en) | Thrombin inhibitors, process for producing them and use of them for producing pharmaceutical compositions | |
BR9908186A (pt) | Processo para produzir endostatina | |
EP1255765A4 (en) | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC TREATMENT OF RHEUMATIC ARTHRITIS | |
DE69903282D1 (de) | Elektrostatisches beschichtungsverfahren und dadurch erhaltene beschichtete produkte | |
AU5241099A (en) | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis | |
DK0980374T3 (da) | Phosphodiesterase 4-inhiberende diazepinoindoloner. | |
PT94993A (pt) | Processo para a preparacao de 17 beta-(ciclopropilamino)-androst-5-en beta-ol 4 substituido e de compostos afins uteis como inibidores de liase c17-c20 | |
PT89958A (pt) | Processo de preparacao de antigenio k5 sulfatado e de fragmentos de antigenio k5 sulfatado, de isolamento de antigenio k5 e preparacao de composicoes farmaceuticas | |
DE69619462D1 (de) | (4R)-cis-4-Methyl-2-substituiertes Tetrahydro-2H-pyranderivat enthaltende Parfumzusammensetzung und Verfahren zur Geruchsverbesserung durch deren Anwendung | |
HUP9600099A3 (en) | Process for producing flavano-lignane compositions of improved release and absorption, compositions produced this way find use of them for producing pharmaceutical compositions | |
HUP0103832A3 (en) | Triazolopyridines for the treatment of thrombosis disorders, pharmaceutical compositions containing the same and process for preparation thereof | |
PL339731A1 (en) | Methods of and compositions for treating rheumatoid arthritis | |
DK0815126T3 (da) | Bicykliske tachykinin-antagonister, fremstilling deraf og deres anvendelse i farmaceutiske præparater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB34 | Technical and formal requirements: requirement - article 34 of industrial property law | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |